Vitamin D3 Supplementation Status and Its Association with Serum Omentin-1, Glycemic Control, and Insulin Resistance in Women with Polycystic Ovary Syndrome: A Cross-Sectional Study
DOI:
https://doi.org/10.70066/jahm.v14i9.3087Keywords:
Glycemic control, Insulin resistance, Omentin-1, Polycystic ovary syndrome, Vitamin D3.Abstract
Background: Polycystic ovary syndrome (PCOS) is a metabolic and endocrine disorder associated with obesity, adipokine dysregulation, insulin resistance, and subfertility. Omentin-1 is an adipokine with anti-inflammatory and insulin-sensitizing properties. Aims: To evaluate the association of vitamin D3 supplementation status with serum omentin-1 levels, glycemic control, and insulin resistance in women with PCOS. Materials and Methods: This cross-sectional study included 105 women aged 16–40 years: 35 healthy controls, 31 women with PCOS without vitamin D3 supplementation, and 39 women with PCOS reporting daily supplementation (400 IU). Serum omentin-1, insulin, and 25-hydroxyvitamin D3 levels were measured using enzyme-linked immunosorbent assays, while fasting blood glucose was determined by colorimetry. Glucose data were available for 103 participants. Insulin resistance was assessed using HOMA-IR. Group differences were evaluated using the Kruskal–Wallis test followed by Dunn’s multiple-comparison test. Multiple linear regression analyses were adjusted for age and body mass index (BMI). Results: After adjustment for age and BMI, vitamin D3 supplementation status was significantly associated with higher serum omentin-1 levels (β = 56.82; 95% CI: 27.92–85.71; P = 0.0002), lower glucose levels (β = −34.34; 95% CI: −39.82 to −28.86; P < 0.0001), and lower HOMA-IR values (β = −1.581; 95% CI: −2.132 to −1.031; P < 0.0001). The association with insulin levels was nonsignificant (β = −1.299; 95% CI: −3.603 to 1.005; P = 0.2644). Conclusion: Vitamin D3 supplementation status was associated with higher omentin-1 levels and lower glucose and HOMA-IR values in women with PCOS. However, the observational design precludes causal inference. Prospective studies are warranted.
References
Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, Kumar M. Polycystic ovary syndrome: etiology, current management, and future therapeutics. Journal of Clinical Medicine. 2023;12(4):1454. Available from: https://doi.org/10.3390/jcm12041454
Koçak İ, Küçükoğlu K. Polycystic ovary syndrome: definition and management. International Journal of Innovative Research and Reviews. 2024;8(2):66–77. Available from: https://izlik.org/JA52FJ77CL
Palomba S, Santagni S, Falbo A, La Sala GB. Complications and challenges associated with polycystic ovary syndrome: current perspectives. International Journal of Women's Health. 2015;7:745–763. Available from: https://doi.org/10.2147/IJWH.S70314
Schüler-Toprak S, Ortmann O, Buechler C, Treeck O. The complex roles of adipokines in polycystic ovary syndrome and endometriosis. Biomedicines. 2022;10(10):2503. Available from: https://doi.org/10.3390/biomedicines10102503
Chen P, Jia R, Liu Y, Cao M, Zhou L, Zhao Z. Progress of adipokines in the female reproductive system: a focus on polycystic ovary syndrome. Front Endocrinol (Lausanne). 2022;13:881684. Available from: https://doi.org/10.3389/fendo.2022.881684
Bohler H, Mokshagundam S, Winters SJ. Adipose tissue and reproduction in women. Fertil Steril. 2010;94(3):795–825. Available from: https://doi.org/10.1016/j.fertnstert.2009.03.079
Orszulak D, Niziński K, Matonóg A, Zięba-Domalik M, Stojko R, Drosdzol-Cop A. Adipokines as biochemical marker of polycystic ovary syndrome in adolescents: review. Front Endocrinol (Lausanne). 2025;16:1475465. Available from: https://doi.org/10.3389/fendo.2025.1475465
Pham TX, Lee JY. Epigenetic regulation of adipokines. Int J Mol Sci. 2017;18(8):1740. Available from: https://doi.org/10.3390/ijms18081740
Al-Mayoofee SH, Missaoui N, Hmissa S, Al-Snafi AE. Adipokines in relation to weight, lipid profile and glycemic state in women with polycystic ovary syndrome. Journal of Obstetrics, Gynecology and Cancer Research. 2024;9(4):422–427. Available from: https://doi.org/10.30699/jogcr.9.4.422
Mohan A, Haider R, Fakhor H, Hina F, Kumar V, Jawed A, et al. Vitamin D and polycystic ovary syndrome (PCOS): a review. Annals of Medicine and Surgery (Lond). 2023;85(7):3506–3511. Available from: https://doi.org/10.1097/MS9.0000000000000879
Choi JH, Rhee EJ, Kim KH, Woo HY, Lee WY, Sung KC. Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. Eur J Endocrinol. 2011;165(5):789–796. Available from: https://doi.org/10.1530/EJE-11-0375
Zhou Y, Zhang B, Hao C, Huang X, Li X, He Y. Omentin—a novel adipokine in respiratory diseases. Int J Mol Sci. 2018; 19(1): 73. Available from: https://doi.org/10.3390/ijms19010073
Rothermel J, Lass N, Barth A, Reinehr T. Link between omentin-1, obesity and insulin resistance in children: findings from a longitudinal intervention study. Pediatr Obes. 2020;15(5):e12605. Available from: https://doi.org/10.1111/ijpo.12605
de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007;56(6):1655–1661. Available from: https://doi.org/10.2337/db06-1506
Guvenc Y, Var A, Goker A, Kuscu NK. Assessment of serum chemerin, vaspin and omentin-1 levels in patients with polycystic ovary syndrome. J Int Med Res. 2016;44(4):796–805. Available from: https://doi.org/10.1177/0300060516645421
Mahde A, Shaker M, Al-Mashhadani Z. Study of omentin-1 and other adipokines and hormones in PCOS patients. Oman Medical Journal. 2009;24(2):108–118. Available from: https://doi.org/10.5001/omj.2009.25
Johnson C, Garipoğlu G, Jeanes Y, Frontino G, Costabile A. The role of diet, glycaemic index and glucose control in polycystic ovary syndrome (PCOS) management and mechanisms of progression. Curr Nutr Rep. 2025;14(1):8. Available from: https://doi.org/10.1007/s13668-024-00601-4
Zhao G, Fan Y, Li R, Huang Y, Li W, Zhao Y, et al. The effectiveness of nutritional supplements in improving polycystic ovary syndrome in women: a systematic review and network meta-analysis. Reprod Biol Endocrinol. 2025; 23(1):94. Available from: https://doi.org/10.1186/s12958-025-01409-9
Ratter-Rieck JM, Zepina A, Niersmann C, Röhrig K, Riols F, Haid M, Lintelmann J, et al. Omentin increases glucose uptake, but not insulin sensitivity in human myotubes dependent on extracellular lactotransferrin. Obes Facts. 2025;18(2):121–129. Available from: https://doi.org/10.1159/000541915
Wurm S, Neumeier M, Weigert J, Schäffler A, Buechler C. Plasma levels of leptin, omentin, collagenous repeat-containing sequence of 26-kDa protein (CORS-26) and adiponectin before and after oral glucose uptake in slim adults. Cardiovasc Diabetol. 2007;6:7. Available from: https://doi.org/10.1186/1475-2840-6-7
Tan BK, Adya R, Farhatullah S, Lewandowski KC, O’Hare P, Lehnert H, et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes. 2008;57(4):801–808. Available from: https://doi.org/10.2337/db07-0990
McArdle MA, Finucane OM, Connaughton RM, McMorrow AM, Roche HM. Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies. Front Endocrinol (Lausanne). 2013;4:52. Available from: https://doi.org/10.3389/fendo.2013.00052
Garg SS, Kushwaha K, Dubey R, Gupta J. Association between obesity, inflammation and insulin resistance: insights into signaling pathways and therapeutic interventions. Diabetes Res Clin Pract. 2023;200:110691. Available from: https://doi.org/10.1016/j.diabres.2023.110691
Wu H, Ballantyne CM. Metabolic inflammation and insulin resistance in obesity. Circ Res. 2020;126(11):1549–1564. Available from: https://doi.org/10.1161/CIRCRESAHA.119.315896
Jin Q, Liu S, Zhang Y, Ji Y, Wu J, Duan H, et al. Severe obesity, high inflammation, insulin resistance with risks of all-cause mortality and all-site cancers, and potential modification by healthy lifestyles. Sci Rep. 2025;15:1472. Available from: https://doi.org/10.1038/s41598-025-85519-9
Hakami AA, Hamzi WA, Alshammari HO, Alshammari TO, Aldfeery FZS, Alanazi ISH, et al. Polycystic ovary syndrome (PCOS): pathophysiology, diagnosis, biomarkers, and nursing interventions. Journal of Medicinal and Chemical Sciences. 2024;7(12):1788–1807. Available from: https://doi.org/10.26655/jmchemsci.2024.12.3
Mohapatra I, Samantaray SR. BMI and polycystic ovary syndrome: demographic trends in weight and health. Cureus Journal of Medical Science. 2024;16(3):e55439. Available from: https://doi.org/10.7759/cureus.55439
Niroomand M, Fotouhi A, Irannejad N, Hosseinpanah F. Does high-dose vitamin D supplementation impact insulin resistance and risk of development of diabetes in patients with pre-diabetes? A double-blind randomized clinical trial. Diabetes Res Clin Pract. 2019;148:1–9. Available from: https://doi.org/10.1016/j.diabres.2018.12.008
Peterson CA, Tosh AK, Belenchia AM. Vitamin D insufficiency and insulin resistance in obese adolescents. Therapeutic Advances in Endocrinology and Metabolism. 2014;5(6):166–189. Available from: https://doi.org/10.1177/2042018814547205
Al-Shami AS, Alzumor M, Aladhal A, Al-Saban A. Association between vitamin D level and insulin resistance among patients with type 2 diabetes mellitus in Sana’a City. BMC Endocr Disord. 2025;25:152. Available from: https://doi.org/10.1186/s12902-025-01972-7
Bhatt SP, Misra A, Pandey RM, Upadhyay AD, Gulati S, Singh N. Vitamin D supplementation in overweight/obese Asian Indian women with prediabetes reduces glycemic measures and truncal subcutaneous fat: a 78 weeks randomized placebo-controlled trial (PREVENT-WIN trial). Sci Rep. 2020;10:220. Available from: https://doi.org/10.1038/s41598-019-56904-y
Nazarian S, St Peter JV, Boston RC, Jones SA, Mariash CN. Vitamin D3 supplementation improves insulin sensitivity in subjects with impaired fasting glucose. Transl Res. 2011;158(5):276–281. Available from: https://doi.org/10.1016/j.trsl.2011.05.002
Kohlhoff G, Kirwan R, Mushtaq S. The effect of vitamin D supplementation on markers of insulin resistance in women with polycystic ovarian syndrome: a systematic review. Eur J Nutr. 2024;63(8):2859–2869. Available from: https://doi.org/10.1007/s00394-024-03489-6
Azuz SEN, Salih ES. Assessment of Serum Omentin-1 Level in Iraqi women with Gestational Diabetes Mellitus. Iraqi Journal of Pharmaceutical Sciences. 2025;33(4SI):290–296. Available from: https://doi.org/10.31351/vol33iss(4SI)pp290-296
Sena CM. Omentin: a key player in glucose homeostasis, atheroprotection, and anti-inflammatory potential for cardiovascular health in obesity and diabetes. Biomedicines. 2024;12(2):284. Available from: https://doi.org/10.3390/biomedicines12020284
AminiLari Z, Fararouei M, Amanat S, Sinaei E, Dianatinasab S, AminiLari M, et al. The effect of 12 weeks aerobic, resistance, and combined exercises on omentin-1 levels and insulin resistance among type 2 diabetic middle-aged women. Diabetes Metab J. 2017;41(3):205–212. Available from: https://doi.org/10.4093/dmj.2017.41.3.205
Molani-Gol R, Rafraf M, Asghari Jafarabadi M, Aftabi-Yousefabad S, Shanehbandi D. Effects of vitamin D supplementation on metabolic factors, serum omentin-1, and anthropometric indices in middle-aged women with prediabetes: a double-blind randomized controlled trial. Nutr Diabetes. 2025;15:44. Available from: https://doi.org/10.1038/s41387-025-00402-w
Cheshmazar E, Hosseini AF, Yazdani B, Razmpoosh E, Zarrati M. Effects of vitamin D supplementation on omentin-1 and spexin levels, inflammatory parameters, lipid profile, and anthropometric indices in obese and overweight adults with vitamin D deficiency under low-calorie diet: a randomized placebo-controlled trial. Evidence-Based Complementary and Alternative Medicine. 2020;2020:3826237. Available from: https://doi.org/10.1155/2020/3826237
Jafari T, Faghihimani E, Feizi A, Iraj B, Javanmard SH, Esmaillzadeh A, et al. Effects of vitamin D-fortified low fat yogurt on glycemic status, anthropometric indexes, inflammation, and bone turnover in diabetic postmenopausal women: a randomised controlled clinical trial. Clin Nutr. 2016;35(1):67–76. Available from: https://doi.org/10.1016/j.clnu.2015.02.014
Amirkhizi F, Khademi Z, Hamedi Shahraki S, Rahimlou M. Vitamin D insufficiency and its association with adipokines and atherogenic indices in patients with metabolic syndrome: a case-control study. Front Endocrinol (Lausanne). 2023;14:1080138. Available from: https://doi.org/10.3389/fendo.2023.1080138
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Zainab H. Fathi, Ammar A.Y. Almulathanon
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain the copyright of their work and grant the Journal of Ayurveda and Holistic Medicine (JAHM) the right of first publication. All published articles are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) license, which permits non-commercial sharing, use, distribution, and adaptation with proper attribution and the same license terms.
JAHM ensures free, irrevocable, worldwide access to its content. Users may copy, distribute, display, and share published works for non-commercial purposes with appropriate credit to the author(s) and the journal. Limited printed copies for personal, non-commercial use are allowed under the same license.
If a submission is not accepted for publication, the author(s) will be notified.
By submitting, authors confirm that the work is original, that all listed authors have contributed and approved it, and that it does not infringe any third-party rights or duplicate work submitted elsewhere.
